Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $72.48M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.15M
Average 0.16M
COYA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Coya Therapeutics, Inc.NASDAQ: COYA
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 42.8% from a year ago
Cash & equivalents stood at $50.72M at the end of Q1 FY2026, up 42.8% from a year earlier and up 8.3% from the prior quarter. Over 3 fiscal years it compounded at +99.1% a year.
Context
- Cash & equivalents amounted to 95.2% of total assets at the end of Q1 FY2026, up 2.7 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +42.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 46.82M USD
- Year-over-year change
- +22.1%
- 4-year CAGR
- +81.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.82M | +22.1% |
| FY2024 | 2024-12-31 | 38.34M | +17.5% |
| FY2023 | 2023-12-31 | 32.63M | +449.9% |
| FY2022 | 2022-12-31 | 5.93M | +36.7% |
| FY2021 | 2021-12-31 | 4.34M | — |
Cash & Equivalents vs competitors
How COYA compares with its peers on the latest reported figures
- COYA's Mar 2026 cash & equivalents of $50.72M is the 6th highest of the 11 companies compared; the peer median is $44.66M.
- Its year-over-year change of +42.8% is the 4th highest of 11, against a peer median of -39.3%.
- Cash & equivalents amounts to 95.2% of total assets for COYA, versus a peer median of 29.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $94.06M | +345.0% | -33.6% | 41.7% | |
| Mar 2026 | $90.42M | +48.5% | +4.6% | 88.5% | |
| Mar 2026 | $79.25M | +397.8% | +91.2% | 82.7% | |
| Mar 2026 | $66.52M | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | $54.53M | -39.0% | +23.0% | 92.6% | |
| Mar 2026 | $50.72M | +42.8% | +99.1% | 95.2% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $34.79M | -84.7% | -1.3% | 27.3% |
| Mar 2026 | $31.93M | -23.8% | -5.8% | 12.6% | |
| Mar 2026 | $22.19M | -75.9% | +10.5% | 11.0% | |
| Mar 2026 | $13.2M | -82.3% | +4.3% | 4.9% | |
| Mar 2026 | $5.94M | -39.6% | -34.3% | 27.4% | |
| Peer median (excluding COYA) | $44.66M | -39.3% | +1.5% | 29.0% | |
Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.34M | 5.93M | 32.63M | 38.34M | 46.82M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 7.5M | 730.58K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 4.58M | 7.18M | 41.2M | 44.31M | 49.94M |
| Property, Plant & Equipment (Net) | 120.67K | 93.31K | 65.95K | 38.59K | 11.23K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 87.18K | 1.12M | 0 | 0 | 0 |
| Total Non-current Assets | 207.85K | 1.21M | 65.95K | 38.59K | 11.23K |
| Total Assets | 4.79M | 8.4M | 41.26M | 44.35M | 49.95M |
| Account Payables | 857.57K | 1.82M | 1.16M | 1.59M | 1.06M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 723.85K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 923.11K | 848.29K | 1.2M |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 1.15M | 3.82M | 5.05M | 3.82M | 5.87M |
| Long-term Debt | 0 | 12.97M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 574.69K | 945.45K | 1.05M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 12.97M | 574.69K | 945.45K | 1.05M |
| Total Liabilities | 1.15M | 16.79M | 5.63M | 4.77M | 6.92M |
| Common Stock | 259 | 259 | 1.44K | 1.67K | 2.09K |
| Retained Earnings | (5.62M) | (17.87M) | (25.86M) | (40.74M) | (61.96M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | (11.25K) | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 3.64M | (8.39M) | 35.64M | 39.58M | 43.03M |
| Total Debt | 0 | 12.97M | 0 | 0 | 0 |
| Net Debt | (4.34M) | 7.03M | (32.63M) | (38.34M) | (46.82M) |
Coya Therapeutics, Inc.
NASDAQ:COYA
Intrinsic Alpha fair value
Locked
Current Price
$3.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.